Pre-clinical Study of ²¹³Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer

By Qu Chang   Song Emma   Li Yong   Rizvi Syed   Raja Chand   Smith Ross   Morgenstern Alfred   Apostolidis C.   Allen Barry  

Clinical and Experimental Metastasis, Vol. 22, Iss. 7, 2005-11 ,pp. : 575-586

Springer Publishing Company

Access to resources Recommend Favorite

Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions

By Daneri-Navarro A.   Macias-Lopez G.   Oceguera-Villanueva A.   Del Toro-Arreola S.   Bravo-Cuellar A.   Perez-Montfort R.   Orbach-Arbouys S.  

European Journal of Cancer, Vol. 34, Iss. 4, 1998-03 ,pp. : 566-569

Elsevier

Access to resources Recommend Favorite

Differential mRNA Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor Type-2 in Normal Human Endometria and Endometrial Carcinomas

By Foca C.   Moses E.K.   Quinn M.A.   Rice G.E.  

Gynecologic Oncology, Vol. 79, Iss. 2, 2000-11 ,pp. : 244-250

Elsevier

Access to resources Recommend Favorite

In Vitro Anti-proliferative and Anti-invasive Role of Amino-terminal Fragment of Urokinase-type Plasminogen Activator on 8701-BC Breast Cancer Cells

By Luparello C.   Del Rosso M.  

European Journal of Cancer, Vol. 32, Iss. 4, 1996-04 ,pp. : 702-707

Elsevier

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite